Envudeucitinib for Systemic Lupus Erythematosus (SLE)

Envudeucitinib is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor designed to correct immune dysregulation across a range of diseases, including SLE, the most common form of lupus. By selectively targeting key proinflammatory mediators, including type 1 interferon (IFN), it aims to deliver maximal inhibition while minimizing off-target effects.

LUMUS: A Phase 2b Clinical Study

The LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall patient population. However, robust clinical responses observed in a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE. In LUMUS, envudeucitinib was well tolerated and demonstrated a favorable safety profile with no new safety signals.